| Variable selection - A review and recommendations for the practicing statistician |
127 |
| When should meta-analysis avoid making hidden normality assumptions? |
20 |
| Neighbor balance and evenness of distribution of treatment replications in row-column designs |
7 |
| Construction of confidence intervals for the maximum of the Youden index and the corresponding cutoff point of a continuous biomarker |
6 |
| Covariate selection strategies for causal inference: Classification and comparison |
5 |
| A coefficient of determination (R-2) for generalized linear mixed models |
5 |
| Multiple testing with discrete data: Proportion of true null hypotheses and two adaptive FDR procedures |
5 |
| Relative efficiency of unequal versus equal cluster sizes in cluster randomized trials using generalized estimating equation models |
5 |
| Effect size measures and their benchmark values for quantifying benefit or risk of medicinal products |
4 |
| Mixtures of Berkson and classical covariate measurement error in the linear mixed model: Bias analysis and application to a study on ultrafine particles |
4 |
| Power priors based on multiple historical studies for binary outcomes |
4 |
| Estimating the DINA model parameters using the No-U-Turn Sampler |
3 |
| Equivalence analyses of dissolution profiles with the Mahalanobis distance |
3 |
| A comparison of model selection methods for prediction in the presence of multiply imputed data |
3 |
| Bivariate random-effects meta-analysis models for diagnostic test accuracy studies using arcsine-based transformations |
3 |
| Dynamic clinical prediction models for discrete time-to-event data with competing risks-A case study on the OUTCOMEREA database |
3 |
| A comparison of machine learning algorithms and covariate balance measures for propensity score matching and weighting |
3 |
| Multiple imputation for discrete data: Evaluation of the joint latent normal model |
3 |
| Marginal false discovery rate control for likelihood-based penalized regression models |
3 |
| A Bayesian joint model of recurrent events and a terminal event |
3 |
| Test-compatible confidence intervals for adaptive two-stage single-arm designs with binary endpoint |
3 |
| Asymptotic distributions of kappa statistics and their differences with many raters, many rating categories and two conditions |
3 |
| Two-stage orthogonality based estimation for semiparametric varying-coefficient models and its applications in analyzing AIDS data |
3 |
| A comparison of different ways of including baseline counts in negative binomial models for data from falls prevention trials |
2 |
| A probabilistic network for the diagnosis of acute cardiopulmonary diseases |
2 |
| Tuning model parameters in class-imbalanced learning with precision-recall curve |
2 |
| Interim analysis incorporating short- and long-term binary endpoints |
2 |
| Multivariate multiple test procedures based on nonparametric copula estimation |
2 |
| Hommel's procedure in linear time |
2 |
| Stabilizing cumulative incidence estimation of pregnancy outcome with delayed entries |
2 |
| Blinded and unblinded sample size reestimation procedures for stepped-wedge cluster randomized trials |
2 |
| Defective regression models for cure rate modeling with interval-censored data |
2 |
| Correct and logical inference on efficacy in subgroups and their mixture for binary outcomes |
2 |
| The hierarchical metaregression approach and learning from clinical evidence |
2 |
| Self-controlled case series studies: Just how rare does a rare non-recurrent outcome need to be? |
2 |
| Bayesian propensity scores for high-dimensional causal inference: A comparison of drug-eluting to bare-metal coronary stents |
2 |
| Reconstruction of molecular network evolution from cross-sectional omics data |
2 |
| On construction of single-arm two-stage designs with consideration of both response and toxicity |
2 |
| Joint regression analysis for survival data in the presence of two sets of semi-competing risks |
2 |
| Optimal sample size allocation and go/no-go decision rules for phase II/III programs where several phase III trials are performed |
2 |
| A cure-rate model for Q-learning: Estimating an adaptive immunosuppressant treatment strategy for allogeneic hematopoietic cell transplant patients |
2 |
| Incorporating historical information in biosimilar trials: Challenges and a hybrid Bayesian-frequentist approach |
2 |
| Bayesian estimation of multivariate normal mixtures with covariate-dependent mixing weights, with an application in antimicrobial resistance monitoring |
2 |
| The one-inflated positive Poisson mixture model for use in population size estimation |
2 |
| Modeling time-varying exposure using inverse probability of treatment weights |
2 |
| Prediction accuracy and variable selection for penalized cause-specific hazards models |
2 |
| Multiple-rater kappas for binary data: Models and interpretation |
2 |
| Optimal promising zone designs |
2 |
| Bayesian hierarchical classification and information sharing for clinical trials with subgroups and binary outcomes |
2 |
| The changing landscape of data monitoring committees-Perspectives from regulators, members, and sponsors |
1 |
